Thymosin Alpha-1

Thymosin Alpha-1 is described as the gold standard for immune modulation in EBV. It retrains the thymus gland to produce mature, competent T-cells — the only cells capable of finding and neutralizing latent EBV-infected B cells. A 2011 study (Stein, International Immunology) showed it increased T-cell count by 38% and T-cell function by 45% specifically in EBV-infected individuals. Hypothetical kangaroo dose: 1 mg twice a week for 12 weeks.

Speaker cites a 2022 study by Prusty in Viruses examining comprehensive HSV management combining immune training peptides, antiviral compounds, nerve repair peptides, and nutrient restoration. Results showed 76% reduction in outbreak frequency, 89% reduction in outbreak severity, 84% reduction in neuropathic pain, with sustained improvement at 12-month follow-up.

Thymosin Alpha-1 administered IM twice weekly retrains the thymus gland to produce elite killer T-cells specifically trained to hunt herpes. Speaker cites a 2015 study by Stein in International Immunology showing TA1 increased HSV-specific CD8+ T-cell count by 156%, T-cell cytotoxicity by 84%, and decreased viral reactivation frequency by 67%.

Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.

Dr. Jones mentions Thymosin Alpha-1 as an immune modulating peptide used in specific clinical settings as part of an advanced autoimmune treatment protocol. He describes it alongside other advanced tools layered on top of foundational root-cause interventions. No dosage or specific protocol details are provided.

The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.

Speaker specifically chose intramuscular (IM) administration for Thymosin Alpha-1, LL-37, and BPC-157 rather than subcutaneous, stating the rationale was faster absorption needed in active viral suppression cases. KPV was the exception, administered subcutaneously.

Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.